A validated HPLC method for the monitoring of thiopurine metabolites in whole blood in paediatric patients with inflammatory bowel disease

被引：0
|
作者：
Cangemi, G. [1 ]
Barco, S. [1 ]
Parodi, A. [1 ]
Bonifazio, P. [1 ]
Vailati, D. [1 ]
Barabino, A. [1 ]
Melioli, G. [1 ]
机构：
[1] Ist Giannina Gaslini, I-16148 Genoa, Italy
来源：
THERAPEUTIC DRUG MONITORING | 2011年 / 33卷 / 04期
关键词：
inflammatory bowel diseases; thiopurine; paediatric; TDM;
D O I：
暂无
中图分类号：
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号：
1001 ;
摘要：
引用
收藏
页码：544 / 545
页数：2
相关论文
共 50 条
  • [41] Limited added value of laboratory monitoring in thiopurine maintenance monotherapy in inflammatory bowel disease patients
    Kreijne, Joany E.
    de Vries, Annemarie C.
    de Veer, Rozanne C.
    Bouma, Gerd
    Dijkstra, Gerard
    Voskuil, Michiel D.
    West, Rachel
    van Moorsel, Sofia A. W.
    de Jong, Dirk J.
    de Boer, Nanne K.
    van der Woude, C. Janneke
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 51 (12) : 1353 - 1364
  • [42] Assessment of general practitioner attitudes towards monitoring thiopurine therapy in inflammatory bowel disease patients
    Wood, E
    Medcalf, L
    McCartney, S
    [J]. GUT, 2006, 55 : A96 - A96
  • [43] Mean Corpuscular Volume to White Blood Cell Ratio for Thiopurine Monitoring in Pediatric Inflammatory Bowel Disease
    Kandavel, Prashanthi
    Eder, Sally J.
    Newman, Noah E.
    Waljee, Akbar K.
    Whitfield, Emily P.
    Adler, Jeremy
    [J]. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2019, 69 (01): : 88 - 94
  • [44] Thiopurine adverse events in patients with inflammatory bowel disease in the UK: inflammatory bowel disease BioResource cohort
    Hong, Y. Y.
    Withanachchi, D. A.
    Aslam, S. P.
    Khalid, Y.
    Shawky, R.
    Parkes, M.
    [J]. JOURNAL OF CROHNS & COLITIS, 2019, 13 : S395 - S396
  • [45] Safety of reduced clinical monitoring in patients with stable Inflammatory Bowel Disease on maintenance thiopurine therapy
    Jansen, E. M.
    Smits, L. S.
    Thomas, P. W. A.
    den Broeder, N.
    de Jong, D. J.
    van Dop, W. A.
    Hoentjen, F.
    [J]. JOURNAL OF CROHNS & COLITIS, 2021, 15 : S492 - S492
  • [46] Therapeutic options for patients with inflammatory bowel disease: Thiopurine immunosuppressants
    Brynskov, J
    [J]. DRUGS OF TODAY, 1997, 33 (06): : 413 - 419
  • [47] Thiopurine methyltransferase and thiopurine metabolite testing in patients with inflammatory bowel disease who are taking thiopurine drugs
    Sheffield, Leslie J.
    Irving, Peter
    Gupta, Arun
    Byron, Keith
    Macrae, Finlay A.
    Phillimore, Hazel
    Dronavalli, Mithilesh
    Rose, Rosemary
    George, Peter
    Walmsley, Trevor
    Dixon, Barbara
    Poole, Susan
    Dooley, Michael
    Sparrow, Miles
    [J]. PHARMACOGENOMICS, 2009, 10 (07) : 1091 - 1099
  • [48] Patients with inflammatory bowel disease who are intolerant to thiopurine treatment
    Karling, P.
    Gensmyr-Singer, H.
    [J]. JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1594 - I1594
  • [49] Adverse events of thiopurine immunomodulators in patients with inflammatory bowel disease
    Lopez-Martin, Cristina
    Chaparro, Maria
    Espinosa, Laura
    Bejerano, Alicia
    Mate, Jose
    Gisbert, Javier P.
    [J]. GASTROENTEROLOGIA Y HEPATOLOGIA, 2011, 34 (06): : 385 - 392
  • [50] Maternal thiopurine metabolism during pregnancy in inflammatory bowel disease and clearance of thiopurine metabolites and outcomes in exposed neonates
    Flanagan, Emma
    Wright, Emily K.
    Hardikar, Winita
    Sparrow, Miles P.
    Connell, William R.
    Kamm, Michael A.
    De Cruz, Peter
    Brown, Steven J.
    Thompson, Alexander
    Greenway, Anthea
    Westley, Ian
    Barclay, Murray
    Ross, Alyson L.
    Kiburg, Katerina V.
    Bell, Sally J.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 53 (07) : 810 - 820
12345